We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hydrogel-Embedded 3-D Scaffold Provides Superior Matrix for Culture of Captured Circulating Tumor Cells

By LabMedica International staff writers
Posted on 17 Aug 2015
Findings obtained by a proof-of-concept study suggested that isolated circulating tumor cells (CTCs) could be induced to grow on three-dimensional scaffolding embedded into a rehydrated hydrogel matrix where they were available for study, manipulation, and transplant.

Improvements in microfluidic technologies have substantially advanced cancer research by enabling the isolation of rare CTCs for diagnostic and prognostic purposes. More...
However, the characterization of isolated CTCs has been limited due to the difficulty in recovering and growing isolated cells with high fidelity.

Investigators at Massachusetts General Hospital (Boston, USA) and their colleagues at Florida State University (Tallahassee, USA) and the University of Massachusetts (Amherst, USA) devised a strategy to substantially improve recovery of CTCs by using a three-dimensional scaffold integrated into a microfludic device. The transferable substrate was readily isolated after device operation for serial use in vivo as a transplanted tissue bed.

In a proof-of-concept study, a dry hydrogel scaffold was inserted into a capture chamber within the fluidic device and then rehydrated to fill the void volume of the capture chamber. Computational modeling was used to define different flow and pressure regimes that guided the conditions used to operate the chip. A cell suspension containing a prostate tumor cell line was used to verify that cancer cells would attach to the hydrogel matrix, which could be directly visualized under a microscope, and grow under these conditions.

Results published in the June 23, 2015, online edition of the journal Technology confirmed human prostate tumor cell attachment in the microfluidic scaffold chip, retrieval of the scaffold en masse, and serial implantation of the scaffold to a mouse model with preserved xenograft development.

"Companion models of circulating tumor cells can be a practical test bed to gain insight about new mutations and drug sensitivity of metastatic cells that can apply to patient care. This proof-of-concept study adds a new dimension to this important effort," said senior author Dr. Biju Parekkadan, assistant professor of surgery at Massachusetts General Hospital.

Related Links:

Massachusetts General Hospital
Florida State University
University of Massachusetts



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.